Article
Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-β therapy in multiple sclerosis patients.
The pharmacogenomics journal - 1 Jun 2012
Weber F, Cepok S, Wolf C, Berthele A, Uhr M, Bettecken Th, Buck D, Hartung H P, Holsboer F, Müller-Myhsok B, Hemmer B
Abstract excerpt
Interferons-β (IFN-β) are the most widely used immunomodulatory drugs for treatment of multiple sclerosis (MS). The development of neutralizing antibodies (NABs) against IFN-β is one of the main reasons for treatment failure. While formulation of the drug has a proven impact on the development of NABs, the genetic predisposition to develop antibodies is poorly understood. We performed genome-wide...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.